Collectively, our research highlights the potential of 5-Aza-CdR, a methylation inhibitor that can rescue KLF5 expression, as a therapeutic modality for the treatment of ccRCC. This evidence concerns the gene KLF5 and nonpapillary renal cell carcinoma.